(NYSE: EVMN) Evommune's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.03%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.07%.
Evommune's earnings in 2026 is -$94,668,000.On average, 13 Wall Street analysts forecast EVMN's earnings for 2026 to be -$102,982,500, with the lowest EVMN earnings forecast at -$117,368,693, and the highest EVMN earnings forecast at -$97,553,200. On average, 13 Wall Street analysts forecast EVMN's earnings for 2027 to be -$115,793,616, with the lowest EVMN earnings forecast at -$171,785,088, and the highest EVMN earnings forecast at -$73,164,900.
In 2028, EVMN is forecast to generate -$121,850,769 in earnings, with the lowest earnings forecast at -$158,981,230 and the highest earnings forecast at -$96,028,931.